Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery
NCT ID: NCT01823562
Last Updated: 2025-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
56 participants
INTERVENTIONAL
2012-10-17
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate
NCT00078923
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer
NCT00450749
Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery
NCT02144649
Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer
NCT01325311
Effects of GCP on Prostate Cancer.
NCT00269555
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To conduct a dose-escalation study to determine safety and compliance of varying lyophilized black raspberry (LBR) delivery vehicles (a gummy confection and a nectar) at two different doses.
SECONDARY OBJECTIVES:
I. To precisely quantify changes in the content and distribution of black raspberry phytochemicals and their metabolites in the blood and urine and correlate these concentrations with prostate tissue phytochemicals.
II. Measure the ability of black raspberry gummy confection and nectar in altering hormonal patterns (lower insulin-like growth factor-1 \[IGF-I\], higher insulin-like growth factor-binding protein 3 \[IGF-BP3\], lower androgens) consistent with reduced prostate carcinogenesis and in parallel with an enhanced capacity to quench reactive oxygen.
III. Investigate histopathologic, immunologic, and molecular biomarkers associated with prostate carcinogenesis that may serve as surrogate endpoint biomarkers and provide information regarding their ability to be modulated by black raspberries.
IV. Determine if consumption of black raspberries alters molecular markers in the human prostate including: (a) neuroendocrine markers such as IGF-I and IGF-BP3, (b) signal transduction markers such as phosphatase and tensin homologue (PTEN) and phospho-AKT, and (c) angiogenesis regulators such as (vascular epithelial growth factor (VEGF).
V. Collect and store plasma and peripheral blood mononuclear cells (PBMCs) from each patient to assess systemic markers of inflammation and immune response.
OUTLINE: This is a dose-escalation study of lyophilized black raspberry gummy confection and nectar. Patients are assigned to 1 of 7 treatment arms.
ARM I: Patients follow a regular diet for 4-6 weeks and then undergo prostatectomy.
ARM II: Patients follow a low polyphenol diet for 4-6 weeks and then undergo prostatectomy.
ARM III: Patients follow a low ellagitannin diet for 4-6 weeks and then undergo prostatectomy.
ARM IV: Patients follow a low ellagitannin diet and receive lower-dose black raspberry gummy orally (PO) daily for 4-6 weeks and then undergo prostatectomy.
ARM V: Patients follow a low ellagitannin diet and receive higher-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
ARM VI: Patients follow a low ellagitannin diet and receive lower-dose black raspberry nectar PO daily for 4-6 weeks and then undergo prostatectomy.
ARM VII: Patients follow a low ellagitannin diet and receive higher-dose black raspberry nectar PO daily for 4-6 weeks and then undergo prostatectomy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (regular diet)
Patients follow a regular diet for 4-6 weeks and then undergo prostatectomy.
laboratory biomarker analysis
Correlative studies
quality-of-life assessment
Ancillary studies
questionnaire administration
Ancillary studies
Arm II (low polyphenol diet)
Patients follow a low polyphenol diet for 4-6 weeks and then undergo prostatectomy.
laboratory biomarker analysis
Correlative studies
dietary intervention
Follow a low polyphenol diet
quality-of-life assessment
Ancillary studies
questionnaire administration
Ancillary studies
Arm III (low ellagitannin diet)
Patients follow a low ellagitannin diet for 4-6 weeks and then undergo prostatectomy.
laboratory biomarker analysis
Correlative studies
dietary intervention
Follow a low ellagitannin diet
quality-of-life assessment
Ancillary studies
questionnaire administration
Ancillary studies
Arm IV (lower-dose lyophilized black raspberry gummy)
Patients follow a low ellagitannin diet and receive lower-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
lyophilized black raspberry confection
Given PO
laboratory biomarker analysis
Correlative studies
dietary intervention
Follow a low ellagitannin diet
quality-of-life assessment
Ancillary studies
questionnaire administration
Ancillary studies
Arm V (higher-dose black raspberry gummy)
Patients follow a low ellagitannin diet and receive higher-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
lyophilized black raspberry confection
Given PO
laboratory biomarker analysis
Correlative studies
dietary intervention
Follow a low ellagitannin diet
quality-of-life assessment
Ancillary studies
questionnaire administration
Ancillary studies
Arm VI (lower-dose black raspberry confection)
Patients follow a low ellagitannin diet and receive lower-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
lyophilized black raspberry confection
Given PO
laboratory biomarker analysis
Correlative studies
dietary intervention
Follow a low ellagitannin diet
quality-of-life assessment
Ancillary studies
questionnaire administration
Ancillary studies
Arm VII (higher-dose black raspberry confection)
Patients follow a low ellagitannin diet and receive higher-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
lyophilized black raspberry confection
Given PO
laboratory biomarker analysis
Correlative studies
dietary intervention
Follow a low ellagitannin diet
quality-of-life assessment
Ancillary studies
questionnaire administration
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lyophilized black raspberry confection
Given PO
laboratory biomarker analysis
Correlative studies
dietary intervention
Follow a low polyphenol diet
dietary intervention
Follow a low ellagitannin diet
quality-of-life assessment
Ancillary studies
questionnaire administration
Ancillary studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have chosen a radical prostatectomy for treatment of their disease after the medical team has presented all possible treatment options
* Not be receiving neoadjuvant hormonal or chemotherapy (other clinical trials)
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
* Not currently taking berry dietary supplements, or "alternative" products (Acai berry, pomegranate, black raspberry, Optiberry, Juice Plus)
* Have BUN/Cr (blood urea nitrogen and serum creatinine) within normal limits
* Have liver enzymes within normal limits
* Have complete blood count (CBC) within normal limits
* Have prothrombin time/partial thromboplastin time (PT/PTT/INR) within normal limits
* Voluntarily agree to participate and sign an informed consent document
* Agree to have prostate biopsy blocks provided to the study for evaluation
* Agree to consume a standardized vitamin and mineral supplement and avoid other nutrition, dietary, or alternative medications/supplements for the duration of the study
* Agree to follow a controlled polyphenolic and/ or ellagitannin diet
Exclusion Criteria
* Have a prostate biopsy with less than 5% cancer involvement
* Have a history of traumatic or surgical castration
* Have a history of pituitary hormone diseases that currently require supplemental hormonal administration (thyroid hormones, adrenocorticotropic hormone \[ACTH\], growth hormone) or other endocrine disorders requiring hormone administration with the exception of diabetes and osteoporosis
* Are taking certain medications; no concurrent finasteride (Proscar) or other hormonal agents for chemoprevention/treatment of benign prostate hyperplasia (BPH); utilizing prescription medications for urinary outlet obstructive symptoms will not be permitted; the use of non-prescription substances to improve urinary tract symptoms will not be permitted (i.e. Saw Palmetto, other herbal, alternative products)
* Have a known allergy to black raspberries, corn, and wheat products or those who have never consumed any of these products
* Have active metabolic or digestive illnesses such as malabsorptive disorders (Crohn's, Celiac disease, irritable bowel syndrome \[IBS\]), renal insufficiency, hepatic insufficiency, cachexia, or short bowel syndrome
* Have significant loss of gastrointestinal organs due to surgery, except for appendix
* Have altered immunity such as autoimmune disorders, cancer, anemia, hemophilia, and blood dyscrasias
* Have noticeable open lesions in the oral cavity, sores that have not healed for more than 2 months or have a history of leukoplakia, tumors of the buccal cavity, throat, and lips
* Have difficulty swallowing (dysphagia), pain with swallowing (odynophagia), salivary gland dysfunction, or xerostomia (dry mouth)
* Are taking medications that inhibit clotting (warfarin sodium) or using prescribed oral rinses (Peridex)
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ohio State University Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Steven Clinton
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven Clinton
Role: PRINCIPAL_INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
The Jamesline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2013-00326
Identifier Type: REGISTRY
Identifier Source: secondary_id
OSU-12125
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.